Rationale and aim

One of the most important determinants of poor outcome after aSAH is rebleeding of the aneurysm. The risk of rebleeding can be diminished or, ideally, obviated by endovascular or neurosurgical treatment of the aneurysm. For decades, neurosurgical clipping was the standard treatment for a ruptured aneurysm. After publication of the ISAT trial, endovascular coiling became the preferred method, if both clipping and coiling were eligible. Additionally, over the last decade advanced endovascular treatment options were introduced, such as balloon- or stent-assisted coiling, flow diverting stents, and intrasaccular devices. Despite these advances and benefits of new endovascular techniques and materials, procedures might also have higher complication rates compared to standard coiling.

Several (mostly single-centre) SAH registries in the world have increased our knowledge on SAH-disease-specific complications (such as rebleeding, delayed cerebral ischemia, hydrocephalus) and long-term outcomes. Registries usually focused on the prevention and treatment of these disease-specific complications and functional or cognitive outcomes, however, they did not capture data on this novel endovascular armamentarium. And notably, regulatory and re-imbursement bodies are increasingly seeking for real-world data on implementation and follow-up of new endovascular devices and techniques.

The MEASURE registry will gather highly detailed data on patients with subarachnoid hemorrhage in current clinical practice in the Netherlands and use this data to answer key clinical questions.